Iodixanol

Details

Stereochemistry	MIXED
Molecular Formula	C35H44I6N6O15
Molecular Weight	1550.1819
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)N(CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I

InChI

InChIKey=NBQNWMBBSKPBAY-UHFFFAOYSA-N

InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)

HIDE SMILES / InChI

Molecular Formula	C35H44I6N6O15
Molecular Weight	1550.1819
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020351s045lbl.pdf

Iodixanol (brand name VISIPAQUE) is an iodine-containing nonionic dimeric hydrophilic contrast agent for intravascular (intravenous and intra-arterial) use during coronary angiography. Pharmacodynamics studies indicated that iodixanol had fewer cardiovascular effects, caused less renal damage and were associated with similar or smaller changes to the blood-brain barrier and neurological function when compared with nonionic contrast media. It is known, that the organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. Thus, after intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cardiovascular diseases 72 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020351s045lbl.pdf	Diagnostic		Approved 8583	VISIPAQUE 270 Approved Use INTRA-ARTERIAL VISIPAQUE Injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography. VISIPAQUE Injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. INTRAVENOUS For information on the concentrations and doses for the pediatric population see the Precautions–Pediatric Use, Clinical Pharmacology–Special Populations, and Dosage and Administration sections. VISIPAQUE Injection (270 mgI/mL) is indicated for CECT imaging of the head and body, excretory urography, and peripheral venography. VISIPAQUE Injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography. Launch Date 1996

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020351s050lbl.pdf	300 mg/kg bw single, intravenous dose: 300 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		IODIXANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
23 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020351s050lbl.pdf	unknown, unknown		IODIXANOL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020351s050lbl.pdf	300 mg/kg bw single, intravenous dose: 300 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:		IODIXANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.44399185336049 g/kg single, intravenous Highest studied dose Dose: 2.44399185336049 g/kg Route: intravenous Route: single Dose: 2.44399185336049 g/kg Sources: https://pubmed.ncbi.nlm.nih.gov/1601604	healthy, 29 years (range: 21-44 years) Health Status: healthy Age Group: 29 years (range: 21-44 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/1601604	Sources: https://pubmed.ncbi.nlm.nih.gov/1601604
651.73116089613 mg/mL single, intrathecal Dose: 651.73116089613 mg/mL Route: intrathecal Route: single Dose: 651.73116089613 mg/mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020351s048,020808s028lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020351s048,020808s028lbl.pdf	Other AEs: Death... Other AEs: Death Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020351s048,020808s028lbl.pdf

AEs

AE	Significance	Dose	Population
Death		651.73116089613 mg/mL single, intrathecal Dose: 651.73116089613 mg/mL Route: intrathecal Route: single Dose: 651.73116089613 mg/mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020351s048,020808s028lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020351s048,020808s028lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31705	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31705
ChemicalBook	CB6465056	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6465056
eMolecules	1987230	https://www.emolecules.com/cgi-bin/more?vid=1987230
MolPort	MolPort-006-167-751	https://www.molport.com/shop/molecule-link/MolPort-006-167-751

PubMed

Title	Date	PubMed
The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells.	2003-10-24	12917397
Identification of organelles in bacteria similar to acidocalcisomes of unicellular eukaryotes.	2003-08-08	12783865
Practical considerations of recombinant adeno-associated virus-mediated gene transfer for treatment of retinal degenerations.	2003-07	12825197
Iodinated contrast media interfere with gel barrier formation in plasma and serum separator tubes.	2003-07	12816919
A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study.	2003-06-18	12821233
[Reduced risk of nepropathy with isoosmolar contrast media].	2003-06-05	12833744
Assessment of organ volume with different techniques using a living liver model.	2003-06	12764643
Nephropathy induced by contrast medium.	2003-05-29	12774814
Nephropathy induced by contrast medium.	2003-05-29	12773659
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].	2003-05-02	12722628
Comparison between the efficacy of dimeric and monomeric non-ionic contrast media (iodixanol vs iopromide) in urography in patients with macroscopic haematuria.	2003-04	12664121
Delayed hypersensitivity reaction to the non-ionic X-ray contrast medium Visipaque (iodixanol).	2003-03	12755737
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol.	2003-03	12659083
Early and late reactions following the use of iopamidol 340, iomeprol 350 and iodixanol 320 in cardiac catheterization.	2003-03	12612387
Protection from contrast-induced nephropathy: is the answer in?	2003-03	12594699
Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.	2003-03	12594698
APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes.	2003-02-28	12471034
Contrast-agent-induced acute renal dysfunction--is iodixanol the answer?	2003-02-06	12571263
Nephrotoxic effects in high-risk patients undergoing angiography.	2003-02-06	12571256
The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets.	2003-02	12871500
Separation of bovine plasma lipoproteins by a rapid ultracentrifugation method.	2003-01	12531683
In vitro stability of tris-acryl gelatin microspheres in a multipharmaceutical chemoembolization solution.	2003-01	12525591
In vivo comparative antithrombotic effects of ioxaglate and iohexol and interaction with the platelet antiaggregant clopidogrel.	2003-01	12496519
Novel tools for production and purification of recombinant adeno-associated viral vectors.	2003	12526168
Tip-growing cells of the moss Ceratodon purpureus Are gravitropic in high-density media.	2002-12	12481093
[Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].	2002-11-20	12439841
Influence of two non-ionic radiographic contrast media with different osmolalities on coagulation in invasive cardiology. A prospective, randomised comparative study.	2002-11	12485262
A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5.	2002-11	12436964
A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.	2002-11	12410513
Purification of lipid rafts from cultured cells.	2002-06-18	12806159
Purification of islets of Langerhans from porcine pancreas.	2002-06-18	12806158
Isolation of peripheral blood mononuclear cells from macaques on a density barrier.	2002-06-15	12806157
Purification of parietal and chief cells from the gastric mucosa.	2002-06-15	12806156
Purification of gastric mucosal ECL cells from a crude elutriation fraction.	2002-06-14	12806154
Isolation of rat and human hippocampal neuron fractions in a discontinuous density gradient.	2002-06-14	12806152
Isolation of human platelets (thrombocytes).	2002-06-12	12806147
Separation of membrane vesicles and cytosol from yeast, cultured cells, and bacteria in a small volume self-generated gradient in a fixed-angle rotor.	2002-06-12	12806146
Separation of membrane vesicles and cytosol from cultured cells and bacteria in a preformed discontinuous gradient.	2002-06-07	12806140
Rapid purification of nuclei from animal and plant tissues and cultured cells.	2002-06-07	12806139
OptiPrep density gradient solutions for macromolecules and macromolecular complexes.	2002-06-07	12806138
Isolation of a mouse motoneuron-enriched fraction from mouse spinal cord on a density barrier.	2002-06-07	12806137
Purification of peroxisomes in a preformed iodixanol gradient in a fixed-angle rotor.	2002-06-07	12806135
Purification of peroxisomes in a self-generated gradient.	2002-06-07	12806134
Fractionation of Golgi, endoplasmic reticulum, and plasma membrane from cultured cells in a preformed continuous iodixanol gradient.	2002-05-22	12805929
Purification of peroxisomes using a density barrier in a swinging-bucket rotor.	2002-05-22	12805925
Purification of intact plant protoplasts by flotation at 1g.	2002-05-21	12805924
Isolation of human polymorphonuclear leukocytes (granulocytes) from a leukocyte-rich fraction.	2002-05-21	12805923
Formation of self-generated gradients of iodixanol.	2002-05-16	12805920
Preparation of preformed iodixanol gradients.	2002-05-16	12805919
Fractionation of hepatic nonparenchymal cells.	2002-05-16	12805918

Patents

Sample Use Guides

In Vivo Use Guide

Intra-arterial digital subtraction angiography (IA-DSA) (270 and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL) Intravenous Dosage and Administration: Computed Tomography of the Head or Body (270 mg Iodine/mL and 320 mg Iodine/mL). Excretory Urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral Venography (270 mg Iodine/mL). Coronary Computed Tomography Angiography (CCTA) (320 mg Iodine/mL).

Route of Administration: Other

In Vitro Use Guide

Contrast media (CM) possess both pro-thrombotic and anticoagulant properties. There were investigated the effect of three classes of CM; Iohexol, Iodixanol and Ioxaglate, on thrombus formation and fibrinolysis in vitro and evaluated the contribution of platelets to this process. Non-anticoagulated blood was mixed with CM or saline (50% or 20% (v/v)) for 1 min then citrated. Thrombus structure was visualized by immunohistochemistry using FITC-fibrinogen antibodies, and propidium iodide to identify nucleated blood cells. Thrombi formed with Iohexol or Iodixanol weighed > OR = 10x more than saline controls (116+/-52 and 230+/-128 mg vs. 11+/-3 mg, respectively; p<0.0005), and were more resistant to thrombolysis as evidenced by the release of FITC over 24 h (19.1+/-8.9 and 31.9+/-17.2 U vs. 65.1+/-19.1 U, respectively; p<0.02).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:29:38 GMT 2025` Edited by `admin` on `Mon Mar 31 18:29:38 GMT 2025`
Record UNII	HW8W27HTXX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Iodixanol

Official Name

English

VISIPAQUE

Preferred Name

English

NSC-760069

Code

English

IODIXANOL [USAN]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, 5,5'-((2-HYDROXY-1,3-PROPANEDIYL)BIS(ACETYLIMINO))BIS(N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-

Common Name

English

IODIXANOL [USP-RS]

Common Name

English

IODIXANOL [ORANGE BOOK]

Common Name

English

Iodixanol [WHO-DD]

Common Name

English

iodixanol [INN]

Common Name

English

IODIXANOL [MI]

Common Name

English

IODIXANOL [VANDF]

Common Name

English

IODIXANOL [USP MONOGRAPH]

Common Name

English

IODIXANOL [USP IMPURITY]

Common Name

English

2-5410-3A

Code

English

IODIXANOL [EP MONOGRAPH]

Common Name

English

IODIXANOL [JAN]

Common Name

English

2-541O-3A

Code

English

IODIXANOL [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28500